Minor Amendment to Announcement of 4th QTR Sales
3 February 2016
Fourth Quarter Sales Update - Significant Sales Growth Continues
The Directors of Promisia Integrative Limited (NZX:PIL) are pleased to advise that
sales for the fourth quarter of the current financial year ending 31 December 2016
have maintained the trend set throughout 2016 year as detailed in the company’s
previous quarterly sales announcements. Sales for the fourth quarter were
$842,576, which is a 485% increase on sales in the same quarter in 2015.
Sales for the full 12 months of 2016 are $2,668,068 compared with sales of
$406,644 for the same period in 2015, which is a 556% increase.
The company also traded profitably for the 4
th
quarter of 2016, and will report the full
year’s annual report in due course.
An independent report shows that Arthrem is currently the No.1 Single selling
product in NZ Pharmacies in dollar terms.
For further information please contact:
Mr Stephen Underwood, Chairman on 499 3412 or 027 499 3387
Mr Charles Daily, Chief Executive Officer on 04 894 8524 or 021 643 906
ENDS
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- EBO — EBOS Group Limited: Half Year Results Presentation2017-02-21
“9 89 100 107 H1 FY15 H1 FY16 H1 FY17 EBITDA NZ$m Healthcare segment Strong trading performances across Australia and New Zealand •Revenue increase of $575m or 21.5% (constant FX): –Australia up 26.8%. –New Zealand up 3.4%. •EBITDA increase of $6.9m or 10.6% (constant FX…”
- CVT — Comvita Limited: Comvita Announces Half Year Results2017-02-20
“Comvita Condensed Interim Financial Statements 2016 - P2Comvita Condensed Interim Financial Statements 2016 - P3 Neil Craig Scott Coulter…”
- EBO — EBOS Group Limited: 2017 Interim Report2017-03-20
“4 It is with great pleasure that we provide you with the interim report for the six months to 31 December 2016 including the highlights of our performance. The interim results reflect the strong operating performance across both our Healthcare and Animal Care segments, and…”